Peptides
They Announced 19 Peptides on Joe Rogan. Nothing's Changed.
RFK Jr. announced 19 peptides on Joe Rogan, but FDA reclassification has not happened yet. Here is the actual GLP-1 and non-GLP-1 peptide timeline.
GLP-1
GLP-1
GLP-1s Are Working. But Your Muscles Are Paying the Price.
GLP-1s deliver incredible weight loss. But 25-40% of weight lost is lean mass. Here's the data on muscle preservation and what to do about it.
GLP-1
The GLP-1 Exit Strategy: What Happens After You Stop?
50-67% of weight returns after stopping GLP-1s. Here's the clinical data on weight regain, muscle loss, and the trial testing the exit.
GLP-1
The GLP-1 Pipeline at a Glance: Oral Drugs, New Agonists, and What Comes Next
2026 is the year of oral GLP-1s. Orforglipron is approved. Oral semaglutide is in Phase 3. The injection-only era is ending.
retatrutide
Retatrutide: The Triple Agonist That Makes GLP-1s Look Basic
Eli Lilly's retatrutide achieved 28.7% weight loss and 76% knee pain reduction in Phase 3. Seven more readouts coming in 2026.
GLP-1
GLP-1s Are Not Being Banned. The Shortcut Is Being Closed.
GLP-1s are not being banned. The FDA is rolling back the 503B bulk-manufacturing shortcut, and patients need more than medication in the mail.
GLP-1
GLP-1 Drugs Are Entering the Alcohol Conversation
A Lancet RCT suggests semaglutide may affect heavy drinking days in adults with alcohol use disorder and obesity—but the story is biology, not hype.
GLP-1
The FDA Just Permanently Ended Bulk Compounded GLP-1s
The FDA's April 30, 2026 proposed rule permanently closes the door on bulk compounded GLP-1s. Here's what that means for your peptide therapy protocol — and your real options.
peptide-therapy
The FDA Is Shutting Down One Peptide Market and Opening Another
Most coverage treats peptide regulation as one story. The reality is bifurcated: GLP-1 copycat compounding is being crushed, while 14 other peptides are being reviewed for restored legal access.